Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 13/20 | 0.53 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15199916 | 1.00 | GAA (0.60) | GAANAAAASAH1NFKB1NFKB2 | |
| SCHEMBL2327582 | 1.00 | GAA (0.60) | GAANAAAASAH1NFKB1NFKB2 | |
| SCHEMBL31384919 | 0.86 | GAA (0.54) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL14502144 | 0.86 | GAA (0.54) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL4152753 | 0.86 | GAA (0.54) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL20581801 | 0.86 | GAA (0.54) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL4985702 | 0.85 | GAA (0.52) | GAANAAAASAH1NFKB1NFKB2 | |
| SCHEMBL7071416 | 0.85 | GAA (0.52) | GAANAAAASAH1NFKB1NFKB2 | |
| SCHEMBL14502146 | 0.84 | GAA (0.51) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL9811313 | 0.83 | GAA (0.57) | GAANAAANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-7432379-B2 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-0413762-B1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN INT INC (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0362902-B1 | Process and intermediates for beta-lactam antibiotics | HARVARD COLLEGE (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5091525-A | 7beta- 2'-(R)-2'-(p-hydroxyphenyl-2'-amino-acetamido!-3-chloro -3-(1-carbadethiacephem)-4-carboxylic acid | ELI LILLY AND COMPANY (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0413762-A4 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | — | 1992-01-15 | — | — | EP | disclosed |
| EP-0209352-B1 | PROCESS AND INTERMEDIATES FOR BETA-LACTAM ANTIBIOTICS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0413762-A1 | PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES | IGEN, INCORPORATED (US) | 1991-02-27 | — | — | EP | disclosed |
| EP-0211540-B1 | INTERMEDIATES AND PROCESS FOR ANTIBIOTICS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1990-05-16 | — | — | EP | disclosed |
| US-4587047-A | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4576749-A | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-03-18 | — | — | US | disclosed |
| US-4559335-A | 3-Acylamino-1-carboxymethyloxy (or thio) carbonyl-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4551277-A | 4-(3-Acylamino-2-oxo-1-azetidinyl)-4-oxo-2-butenoic acid | E. R. SQUIBB & SONS, INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0061765-B1 | BETA-LACTAMS | E.R. SQUIBB & SONS, INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4478749-A | AMINO ACID DERTIVATIVES ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1984-10-23 | — | — | US | disclosed |
| EP-0095394-A2 | 2-Oxo-1-(thiophosphonic or thiophosphinic)-azetidines | E.R. Squibb & Sons, Inc. (US) | 1983-11-30 | — | — | EP | disclosed |
| EP-0062876-A1 | 2-Oxo-1-(((substituted sulfonyl)amino)carbonyl)azetidines | E.R. Squibb & Sons, Inc. (US) | 1982-10-20 | — | — | EP | disclosed |
| EP-0061765-A1 | Beta-Lactams | E.R. SQUIBB & SONS, INC. (US) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275334-A1 | LINEAR PEPTIDE ANTIBIOTICS | SPAST, PEPD, NPEPPS | GAA 423/4885NAAA 431/4885ASAH1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.